EUCTR2015-005356-99-ESActive, not recruitingPhase 1
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes - PRONTO-T1D
illy S.A.0 sites1,328 target enrollmentStarted: April 4, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 1,328
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •You were diagnosed with type 1 diabetes at least one year ago.
- •You are 18 years old or older.
- •You are already using a long-acting insulin and rapid-acting insulin analog.
- •Your blood glucose levels are within allowed limits for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 754
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 251
Exclusion Criteria
- •You have had more than 1 emergency treatment for very low blood glucose in the last 6 months.
- •You have had more than 1 emergency treatment for poor glucose control in the last 6 months.
- •You are taking certain diabetes medications that are not allowed for study participation.
- •You have major problems with your heart, kidneys, liver, or you have a blood disorder.
- •You have had or are now being treated for certain types of cancer that prevents you from study participation.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER1,392
Active, not recruiting
Phase 1
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.Type 1 DiabetesEUCTR2015-005356-99-GREli Lilly and Company1,199
Active, not recruiting
Not Applicable
A Prospective, Randomized, Double-Blind Comparisonof a Long-Acting Basal Insulin Analog LY2963016 toLantus® in Adult Patients with Type 2 Diabetes Mellitus - The ELEMENT 2 Studytype 2 diabetes mellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-000828-15-DEEli Lilly and Company792
Active, not recruiting
Phase 1
A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetesDiabetes Mellitus, Type 1EUCTR2017-003399-30-ATEli Lilly and Company632
Active, not recruiting
Phase 1
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-PLEli Lilly and Company1,392